DFTX Piper Sandler raised the firm's price target on Definium Therapeutics to $73 from $48 and keeps an Overweight rating on the shares. The
DFTX Piper Sandler raised the firm's price target on Definium Therapeutics to $73 from $48 and keeps an Overweight rating on the shares. The firm says its thinking is not only a nod to a favorable readthrough to the upcoming Phase III results in generalized anxiety disorder, but also a nod to what in its view will be a